Company news
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news
Apellis Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 29, 2021: Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second…
Press releases — page 4
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
July 28, 2021
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 25, 2021
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 6, 2021
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
June 29, 2021
Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
June 22, 2021
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
May 24, 2021
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 13, 2021
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
April 27, 2021
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
April 12, 2021
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
March 9, 2021
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 25, 2021
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 6, 2021
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
December 6, 2020
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
November 18, 2020
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
November 15, 2020
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
November 12, 2020
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 1, 2020
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
October 26, 2020
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
October 18, 2020
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
October 14, 2020
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
October 4, 2020
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
October 2, 2020
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
September 20, 2020
Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
September 14, 2020
Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
July 30, 2020
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
July 6, 2020
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
July 1, 2020
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
June 11, 2020
Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
June 9, 2020
Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
May 27, 2020
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 20, 2020
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
May 6, 2020
Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
April 28, 2020
Paul Fonteyne Joins Apellis Board of Directors
April 5, 2020
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
January 6, 2020
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
November 4, 2019
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
September 15, 2019
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
September 11, 2019
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
September 10, 2019